Colony-Stimulating Factors in the Therapeutic Approach to Sepsis

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2000 Nov 30

PMID 11095791

Authors

Alcid

Mathew

Affiliations

Soon will be listed here.

Abstract

Sepsis and its complications continue to be a leading cause of death in the United States despite availability of potent broad-spectrum antimicrobial agents. Current in vitro, ex vivo, animal, and human data are reviewed. Present data shows that colony-stimulating factors (CSFs), granulocyte CSFs, and granulocyte-macrophage CSFs are very effective in raising the leukocyte count and shortening the number of neutropenic days. CSFs in some studies improved outcome of neutropenic septic patients especially when given very early. However, there are studies that do not show any benefit. CSFs appear to be safe and should be limited to septic, neutropenic patients whose duration of neutropenia is anticipated to be prolonged, or to patients who are seriously ill.

References

Parrillo J . Pathogenetic mechanisms of septic shock. N Engl J Med. 1993; 328(20):1471-7. DOI: 10.1056/NEJM199305203282008. View

Bradley T, Metcalf D . The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci. 1966; 44(3):287-99. DOI: 10.1038/icb.1966.28. View

Vidal F, Mensa J, Almela M, Martinez J, Marco F, Casals C . Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 1996; 156(18):2121-6. View

Weinstein M, Murphy J, Reller L, Lichtenstein K . The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis. 1983; 5(1):54-70. DOI: 10.1093/clinids/5.1.54. View

Nelson S, Bagby G . Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis. Clin Chest Med. 1996; 17(2):319-32. DOI: 10.1016/s0272-5231(05)70317-8. View

Keel M, Ungethum U, Steckholzer U, Niederer E, Hartung T, Trentz O . Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood. 1997; 90(9):3356-63. View

Roilides E, Walsh T, Pizzo P, Rubin M . Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis. 1991; 163(3):579-83. DOI: 10.1093/infdis/163.3.579. View

Lundblad R, Wang M, Kvalheim G, Lingaas E, Giercksky K . Granulocyte colony-stimulating factor improves myelopoiesis and host defense in fulminant intra-abdominal sepsis in rats. Shock. 1995; 4(1):68-73. DOI: 10.1097/00024382-199507000-00011. View

Liang D, Chen S, Lean S . Role of granulocyte colony-stimulating factor as adjunct therapy for septicemia in children with acute leukemia. Am J Hematol. 1995; 48(2):76-81. DOI: 10.1002/ajh.2830480202. View

10.

Dale D, Liles W, Summer W, Nelson S . Review: granulocyte colony-stimulating factor--role and relationships in infectious diseases. J Infect Dis. 1995; 172(4):1061-75. DOI: 10.1093/infdis/172.4.1061. View

11.

Atkinson K, BIGGS J, Downs K, Juttner C, Bradstock K, Lowenthal R . GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and lymphocytes. Aust N Z J Med. 1991; 21(5):686-92. DOI: 10.1111/j.1445-5994.1991.tb01371.x. View

12.

Vellenga E, Uyl-de Groot C, de Wit R, Keizer H, Lowenberg B, Ten Haaft M . Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol. 1996; 14(2):619-27. DOI: 10.1200/JCO.1996.14.2.619. View

13.

Pinner R, Teutsch S, Simonsen L, Klug L, Graber J, Clarke M . Trends in infectious diseases mortality in the United States. JAMA. 1996; 275(3):189-93. View

14.

Roilides E, Lyman C, Mertins S, Cole D, Venzon D, Pizzo P . Ex vivo effects of macrophage colony-stimulating factor on human monocyte activity against fungal and bacterial pathogens. Cytokine. 1996; 8(1):42-8. DOI: 10.1006/cyto.1996.0006. View

15.

Anaissie E, Vartivarian S, Bodey G, LeGrand C, Kantarjian H, Abi-Said D . Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. Am J Med. 1996; 100(1):17-23. DOI: 10.1016/s0002-9343(96)90006-6. View

16.

Elting L, Rubenstein E, Rolston K, Bodey G . Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25(2):247-59. DOI: 10.1086/514550. View

17.

Faist E, Kim C . Therapeutic immunomodulatory approaches for the control of systemic inflammatory response syndrome and the prevention of sepsis. New Horiz. 1998; 6(2 Suppl):S97-102. View

18.

Nelson S, Belknap S, Carlson R, Dale D, deBoisblanc B, Farkas S . A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect Dis. 1998; 178(4):1075-80. DOI: 10.1086/515694. View

19.

Bermudez L, Martinelli J, Gascon R, Wu M, Young L . Protection against gram-negative bacteremia in neutropenic mice with recombinant granulocyte-macrophage colony-stimulating factor. Cytokine. 1990; 2(4):287-93. DOI: 10.1016/1043-4666(90)90030-w. View

20.

Bodey G, Buckley M, SATHE Y, Freireich E . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64(2):328-40. DOI: 10.7326/0003-4819-64-2-328. View